vtp-43742
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2015 (NCT03724292)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Nuclear receptor ROR-gammaINHIBITOR
RORC inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- vtp-43742
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02555709 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2015 | Vitae Pharmaceuticals |
| NCT03724292 | Phase 1 | Aug 1, 2015 | Allergan PLC (2015), Vitae Pharmaceuticals |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Vitae Pharmaceuticals | For profit | 2 | 1 | 2 | 2015 |
| Allergan PLC (2015) | For profit | 1 | 1 | 1 | 2015 |
2 organizations
Page 1 / 1